Advancing Critical Care |
INOMAX® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
INOMAX Important Safety Information (ISI)
INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
About Ikaria
Ikaria® is a critical care company focusing on the development and commercialization of innovative therapies that address the significant needs of critically ill patients. The company’s lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. Ikaria offers this therapy through the INOMAX therapy package, an all-inclusive portfolio of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support.
We are proud to bring this important therapy to clinicians and patients in the United States and have been doing so since 1999.
Ikaria also markets the INOMAX therapy package in Puerto Rico, Canada, Australia, Mexico, and Japan.
